• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病的基层医疗管理。

Management of NAFLD in primary care settings.

机构信息

Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.

School of Public Health, University of Haifa, Haifa, Israel.

出版信息

Liver Int. 2022 Nov;42(11):2377-2389. doi: 10.1111/liv.15404. Epub 2022 Sep 1.

DOI:10.1111/liv.15404
PMID:35986897
Abstract

Non-alcoholic fatty liver disease (NAFLD) affects at least 25% of the general population and is an increasingly important cause of cirrhosis and hepatocellular carcinoma. Although it is the research focus of the hepatology field, it is clear that primary care physicians are seeing the majority of NAFLD patients and are in a pivotal position to provide quality care. In this article, we review the role of primary care in the management of NAFLD. NAFLD is common in patients with diabetes, obesity and other metabolic risk factors. Abdominal ultrasonography is the most commonly used method to diagnose fatty liver. Simple fibrosis scores have high negative predictive values in excluding advanced liver fibrosis and future liver-related events and can be used in primary care as initial evaluation. An abnormal result should be followed by subsequent workup or specialist referral. Primary care is the ideal setting to institute multidisciplinary care, especially the involvement of dietitians and physical activity trainers in lifestyle intervention, as well as initiating the discussion of bariatric surgery in patients with severe obesity. Although specific drug treatment for steatohepatitis would require a more precise diagnosis, metabolic drugs that improve both steatohepatitis and cardiovascular outcomes (e.g. glucagon-like peptide-1 receptor agonists) may be considered in patients with NAFLD.

摘要

非酒精性脂肪性肝病(NAFLD)影响至少 25%的普通人群,是肝硬化和肝细胞癌的一个越来越重要的病因。尽管它是肝病学领域的研究重点,但显然初级保健医生正在接诊大多数 NAFLD 患者,并且处于提供优质护理的关键位置。在本文中,我们复习了初级保健在 NAFLD 管理中的作用。NAFLD 在患有糖尿病、肥胖症和其他代谢危险因素的患者中很常见。腹部超声检查是诊断脂肪肝最常用的方法。简单的纤维化评分在排除晚期肝纤维化和未来的肝脏相关事件方面具有很高的阴性预测值,可以在初级保健中作为初始评估使用。异常结果应随后进行进一步检查或专科转诊。初级保健是实施多学科护理的理想场所,特别是营养师和体力活动培训师参与生活方式干预,以及在严重肥胖患者中讨论减重手术。虽然对于脂肪性肝炎的特定药物治疗需要更精确的诊断,但对于同时改善脂肪性肝炎和心血管结局的代谢药物(例如胰高血糖素样肽-1 受体激动剂)可能会被考虑用于 NAFLD 患者。

相似文献

1
Management of NAFLD in primary care settings.非酒精性脂肪性肝病的基层医疗管理。
Liver Int. 2022 Nov;42(11):2377-2389. doi: 10.1111/liv.15404. Epub 2022 Sep 1.
2
Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.非酒精性脂肪性肝病治疗在 2 型糖尿病患者中;新的问题出现了。
Curr Vasc Pharmacol. 2020;18(2):172-181. doi: 10.2174/1570161117666190405164313.
3
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).美国临床内分泌学会临床实践指南:原发性保健和内分泌学临床环境中非酒精性脂肪性肝病的诊断和管理:由美国肝病研究协会(AASLD)共同赞助。
Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.
4
Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.基层医疗临床医生对非酒精性脂肪性肝病认识不足:对纤维化替代标志物的认识有限。
Intern Med J. 2018 Feb;48(2):144-151. doi: 10.1111/imj.13667.
5
Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?非酒精性脂肪性肝病:基层医生需要了解什么?
Am J Med. 2020 May;133(5):536-543. doi: 10.1016/j.amjmed.2020.01.007. Epub 2020 Feb 1.
6
Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.非酒精性脂肪性肝病和 2 型糖尿病患者的发病机制、筛查方式和治疗选择。
Diabet Med. 2020 Nov;37(11):1793-1806. doi: 10.1111/dme.14356. Epub 2020 Jul 13.
7
Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes.在合适的时间、合适的地点为非酒精性脂肪性肝病(NAFLD-RRR 研究)提供正确的护理:2 型糖尿病患者社区护理途径的研究方案。
BMC Health Serv Res. 2022 Apr 12;22(1):487. doi: 10.1186/s12913-022-07808-7.
8
Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai'i.非酒精性脂肪性肝病:夏威夷初级保健提供者的重要考虑因素。
Hawaii J Health Soc Welf. 2020 Jun 1;79(6):180-186.
9
Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.前瞻性评估非酒精性脂肪性肝病患者的初级保健转诊途径。
J Hepatol. 2019 Aug;71(2):371-378. doi: 10.1016/j.jhep.2019.03.033. Epub 2019 Apr 6.
10
Nonalcoholic fatty liver disease: a systematic review.非酒精性脂肪性肝病:系统评价。
JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370.

引用本文的文献

1
Global, regional, and national burden of NASH related liver cancer in adults aged 45 and above: an analysis from the GBD 2021 and forecast to 2050.45岁及以上成年人中与非酒精性脂肪性肝炎相关的肝癌的全球、区域和国家负担:来自全球疾病负担研究(GBD)2021的分析及到2050年的预测
Front Nutr. 2025 Aug 19;12:1651357. doi: 10.3389/fnut.2025.1651357. eCollection 2025.
2
Managing Nonalcoholic Fatty Liver Disease Through Structured Lifestyle Modification Interventions.通过结构化生活方式改变干预措施管理非酒精性脂肪性肝病
Am J Lifestyle Med. 2025 May 26:15598276251346717. doi: 10.1177/15598276251346717.
3
Challenges and needs in the management of non-alcoholic fatty liver disease from the perspective of gastroenterology and hepatology specialists: a qualitative study.
从胃肠病学和肝病学专家角度看非酒精性脂肪性肝病管理中的挑战与需求:一项定性研究
BMC Gastroenterol. 2025 May 22;25(1):396. doi: 10.1186/s12876-025-03921-z.
4
Mitochondrial mt12361A>G increased risk of metabolic dysfunction-associated steatotic liver disease among non-diabetes.线粒体mt12361A>G增加了非糖尿病患者中代谢功能障碍相关脂肪性肝病的风险。
World J Gastroenterol. 2025 Mar 14;31(10):103716. doi: 10.3748/wjg.v31.i10.103716.
5
Racial Disparities in Mortality Rates among Patients with Hepatic Steatosis, Non-Alcoholic Fatty Liver Disease, and Non-Alcoholic Steatohepatitis: Insights from NHANES III Data.肝脂肪变性、非酒精性脂肪性肝病和非酒精性脂肪性肝炎患者死亡率的种族差异:来自美国国家健康和营养检查调查(NHANES)III数据的见解
J Racial Ethn Health Disparities. 2025 Mar 4. doi: 10.1007/s40615-025-02317-9.
6
Global, regional, and national burden of NAFLD in youths and young adults aged 15-39 years, 1990-2021, its attributable risk factors, and projections to 2035: a systematic analysis of the Global Burden of Disease Study 2021.1990年至2021年15至39岁青少年和青年非酒精性脂肪性肝病的全球、区域和国家负担、其可归因风险因素以及到2035年的预测:全球疾病负担研究2021的系统分析
Front Nutr. 2025 Jan 28;12:1509232. doi: 10.3389/fnut.2025.1509232. eCollection 2025.
7
Dietary Interventions and Physical Activity as Crucial Factors in the Prevention and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.饮食干预和体育活动是预防和治疗代谢功能障碍相关脂肪性肝病的关键因素。
Biomedicines. 2025 Jan 16;13(1):217. doi: 10.3390/biomedicines13010217.
8
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025.4. 合并症的综合医学评估与评定:2025年糖尿病照护标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S59-S85. doi: 10.2337/dc25-S004.
9
The effect of probiotic supplementation on non-alcoholic fatty liver disease (NAFLD) fibrosis score in patients attending a tertiary hospital clinic in Cairo, Egypt.埃及开罗一家三级医院诊所的患者中,益生菌补充对非酒精性脂肪性肝病(NAFLD)纤维化评分的影响。
BMC Gastroenterol. 2024 Oct 8;24(1):354. doi: 10.1186/s12876-024-03424-3.
10
Towards unification of liver stiffness measurement cutoffs: Editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis".迈向肝硬度测量临界值的统一:关于“振动控制瞬时弹性成像和磁共振弹性成像在诊断非酒精性脂肪性肝病患者晚期肝纤维化中的最佳临界值:一项系统评价和荟萃分析”的社论
Clin Mol Hepatol. 2025 Jan;31(1):264-267. doi: 10.3350/cmh.2024.0766. Epub 2024 Sep 20.